A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF

Inclusion Criteria:

- Patients with myelofibrosis requiring therapy

- Evidence of post-menopausal status or sterile

- ECOG Performance Status
Exclusion Criteria:

- Prior therapy with any JAK2 medications

- Significant lung disorder or lung disease

- Previous radiation therapy to chest wall or chest infection requiring antibiotic
treatment within 28 days before study screening

- Eye disease of the cornea

- Patients requiring oxygen supplementation

- Ejection fraction <45% (ECHO/MUGA) or significant pulmonary hypertension >40 mm Hg
(by Echo/Doppler)

- Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) <70% predicted or >130%
predicted

- Diffusing capacity of the Lung for Carbon Monoxide (DLCO) corrected for hemoglobin
<60% predicted, oxygen saturation <88% at rest or after a 6-minute flat walk, without
supplemental oxygen

- Chest infection requiring antibiotics within 7 days of the first dose of
Investigational product.